Back to today’s briefing

Story perspectives

OrderlyMeds Defies Eli Lilly, Sells Controversial Tirzepatide

4/11/2025

27 4

Summary

Story summary

OrderlyMeds defiantly sells compounded tirzepatide, ignoring Eli Lilly's cease and desist letter, and touts its commitment to personalized healthcare. Meanwhile, the FDA asserts there's no shortage of the drug, restricting pharmacies to modified versions. As legal battles brew over patent rights, the FDA's new leadership faces mounting scrutiny in this escalating conflict.

1 of 1

Story summary

OrderlyMeds defiantly sells compounded tirzepatide, ignoring Eli Lilly's cease and desist letter, and touts its commitment to personalized healthcare. Meanwhile, the FDA asserts there's no shortage of the drug, restricting pharmacies to modified versions. As legal battles brew over patent rights, the FDA's new leadership faces mounting scrutiny in this escalating conflict.